HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma

Files in This Item:
manuscript.pdf1.08 MBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/61985

Title: Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma
Authors: Mizumachi, Takatsugu Browse this author →KAKEN DB
Homma, Akihiro Browse this author →KAKEN DB
Kakizaki, Tomohiko Browse this author
Sakashita, Tomohiro Browse this author →KAKEN DB
Kano, Satoshi Browse this author →KAKEN DB
Hatakeyama, Hiromitsu Browse this author →KAKEN DB
Tsuchiya, Kazuhiko Browse this author →KAKEN DB
Yasuda, Koichi Browse this author →KAKEN DB
Onimaru, Rikiya Browse this author →KAKEN DB
Shirato, Hiroki Browse this author →KAKEN DB
Taguchi, Jun Browse this author
Shimizu, Yasushi Browse this author →KAKEN DB
Kinoshita, Ichiro Browse this author →KAKEN DB
Akita, Hirotoshi Browse this author →KAKEN DB
Fukuda, Satoshi Browse this author →KAKEN DB
Keywords: Head and neck cancer
Induction chemotherapy
Chemoradiotherapy
Issue Date: Jun-2015
Publisher: Springer
Journal Title: International journal of clinical oncology
Volume: 20
Issue: 3
Start Page: 431
End Page: 437
Publisher DOI: 10.1007/s10147-014-0726-y
PMID: 24993675
Abstract: The aim of this study was to evaluate the feasibility of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Between 2010 and 2013, 30 patients with Stage IV HNSCC were treated in Hokkaido University Hospital with three cycles of induction chemotherapy (docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), day 1; and 5-fluorouracil 750 mg/m(2)/day 120 h continuous infusion, every 3 weeks) followed by concurrent weekly cisplatin (40 mg/m(2), on weeks 1, 2, 3, 5, 6 and 7) chemoradiotherapy. Three courses of induction chemotherapy were performed in 25 patients (83 %) with grade 3-4 toxicities during induction chemotherapy observed in 22 patients (73 %). The major toxicities were hematologic, with 22 cases (73 %) showing grade 3-4 neutropenia. Radiotherapy was completed (70 Gy) in 29 patients (97 %), while a total of 19 patients (63 %) completed five (13 patients) or six (6 patients) courses of chemotherapy. During concurrent chemoradiotherapy, no grade 4 hematological toxicities were observed. Grade 4 dermatitis was observed in one patient, and grade 3 mucositis was observed in 12 patients. There were no treatment-related deaths during the induction chemotherapy or concurrent chemoradiotherapy. The 1- and 2-year progression-free survival rates and the 1- and 2-year overall survival rates were 86 %, 72 %, and 89 %, 81 %, respectively. Sequential therapy composed of induction chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy is feasible, showing encouraging results in patients with locally advanced HNSCC. Concurrent weekly cisplatin chemoradiotherapy following induction chemotherapy appears to be a suitable alternative to three-weekly high-dose cisplatin therapy.
Rights: The final publication is available at Springer via http://dx.doi.org/10.1007/s10147-014-0726-y
Type: article (author version)
URI: http://hdl.handle.net/2115/61985
Appears in Collections:国際連携研究教育局 : GI-CoRE (Global Institution for Collaborative Research and Education : GI-CoRE) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 水町 貴諭

Export metadata:


 

Feedback - Hokkaido University